Treatment outcomes and safety of oral β-blockers and sirolimus in children with kaposiform hemangioendothelioma: a single-center retrospective cohort study

OBJECTIVE: To describe outcomes and safety of oral β-blockers and sirolimus in children with kaposiform hemangioendothelioma (KHE). METHODS: We retrospectively reviewed children with KHE receiving oral β-blockers or sirolimus at Beijing Children's Hospital from January 2016 to April 2026. Lesion regression at fixed time points, treatment duration, treatment discontinuation, recurrence, and safety were assessed. RESULTS: = 0.003). Cumulative lesion-regression thresholds did not differ significantly through 9 months. At 9 months, >25%, >50%, and >75% regression occurred in 76.9%, 46.2%, and 23.1% with β-blockers versus 100.0%, 72.7%, and 18.2% with sirolimus, respectively. Treatment was discontinued in 9/13 and 3/11 patients (median durations, 40.0 and 18.0 months, respectively). No recurrence was observed after cessation. Safety events were reversible and manageable. CONCLUSIONS: In this cohort, both treatments were associated with improvement, but baseline imbalances limit direct comparison. β-blocker responses in predominantly younger, less symptomatic patients require confirmation in larger prospective studies.

Authors

Institutions

Publication Details

Journal
Journal of Dermatological Treatment
Published
2026-11-18
DOI
https://doi.org/10.1080/09546634.2026.2756040
Primary Topic
Vascular Malformations and Hemangiomas
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Treatment outcomes and safety of oral β-blockers and sirolimus in children with kaposiform hemangioendothelioma: a single-center retrospective cohort study

Yi Tian, Ma Lin, Li Wei, Li Li
Journal of Dermatological Treatment
Vascular Malformations and Hemangiomas
article

Treatment outcomes and safety of oral β-blockers and sirolimus in children with kaposiform hemangioendothelioma: a single-center retrospective cohort study

Yi Tian, Ma Lin, Li Wei, Li Li
article en

Abstract

OBJECTIVE: To describe outcomes and safety of oral β-blockers and sirolimus in children with kaposiform hemangioendothelioma (KHE). METHODS: We retrospectively reviewed children with KHE receiving oral β-blockers or sirolimus at Beijing Children's Hospital from January 2016 to April 2026. Lesion regression at fixed time points, treatment duration, treatment discontinuation, recurrence, and safety were assessed. RESULTS: = 0.003). Cumulative lesion-regression thresholds did not differ significantly through 9 months. At 9 months, >25%, >50%, and >75% regression occurred in 76.9%, 46.2%, and 23.1% with β-blockers versus 100.0%, 72.7%, and 18.2% with sirolimus, respectively. Treatment was discontinued in 9/13 and 3/11 patients (median durations, 40.0 and 18.0 months, respectively). No recurrence was observed after cessation. Safety events were reversible and manageable. CONCLUSIONS: In this cohort, both treatments were associated with improvement, but baseline imbalances limit direct comparison. β-blocker responses in predominantly younger, less symptomatic patients require confirmation in larger prospective studies.

Journal of Dermatological TreatmentVol. 37(1)
Ministry of Education of the People's Republic of China (CN), Capital Medical University (CN), Beijing Children’s Hospital (CN)
Vascular Malformations and Hemangiomas
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon